Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis

Autor: Andrey E. Dorofeyev, Wolfgang Kruis, Marina Pesegova, Britta Siegmund, Konstantin Soloviev, Yuriy Mostovoy, Viacheslav Neshta, Yuriy Lozynskyy, Michael Vieth, Roland Greinwald, Pavel Andreev, Ralf Mohrbacher, Olga Alekseeva, Michael Stiess, Olena Levchenko, Sayar Abdulkhakov, Oleksii Datsenko

Publikováno v: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 17(1)

Background & Aims Although proctitis is the most limited form of ulcerative colitis, it causes unpleasant symptoms. Topical mesalamine, the standard treatment, is not always effective. We conducted a randomized phase 2 trial to determine the efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7417a091e52cb9f1abc6c50c08ae44f1
https://pubmed.ncbi.nlm.nih.gov/29702300

Изменения экспрессии MUC2, MUC3, MUC4, TFF3 в слизистой оболочке толстого кишечника у больных неспецифическим язвенным колитом

Autor: Andrey E. Dorofeyev, O.A. Rassokhina, I.V. Vasilenko

Publikováno v: GASTROENTEROLOGY; № 1.47 (2013); 80-84
Гастроэнтерология-Gastroenterologìa; № 1.47 (2013); 80-84
Гастроентерологія-Gastroenterologìa; № 1.47 (2013); 80-84

The aim of this study was to evaluate the changes in expression of mucins (MUC2, MUC 3, MUC 4) and trefoil peptide (TFF3) of colonic mucus barrier in patients with ulcerative colitis (UC). 49 patients with left-side UC in the acute stage were examine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::833a828084cab426e73c6febd002f531
https://doi.org/10.22141/2308-2097.1.47.2013.86251

Phase III Randomized, Double-Blind, Controlled Trial to Compare Biosimilar Infliximab (CT-P13) with Innovator Infliximab (INX) in Patients with Active Crohn's Disease: Early Efficacy and Safety Results

Autor: Sigal Fishman, Kang-Moon Lee, Andrey E. Dorofeyev, Sang Joon Lee, Chang Soo Eun, Maria Lia Scribano, Olena Levchenko, Marina Pesegova, Ágnes Salamon, Young Ho Kim, Olga Alexeeva, M F Osipenko, Adi Lahat, Jae Hee Cheon, Radu-Bogdan Mateescu, Sung Young Lee, Byong Duk Ye

Publikováno v: Gastroenterology. 152:S65

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::26d6ab1c70f3595201f4c0f191226c6d
https://doi.org/10.1016/s0016-5085(17)30571-1

DOP061 Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results

Autor: Adi Lahat, Ágnes Salamon, Chang-Soo Eun, Andrey E. Dorofeyev, Jae Hee Cheon, O. Levchenko, M. Pesegova, Sigal Fishman, Yoon-Goo Kim, O. Alexeeva, Byong Duk Ye, S.Y. Lee, Radu Bogdan Mateescu, S J Lee, Maria Lia Scribano, M. Osipenko, Kang-Moon Lee

Publikováno v: Journal of Crohn's and Colitis. 11:S62-S62

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d940b8fb48e8e463d9be5e427ab5f4a
https://doi.org/10.1093/ecco-jcc/jjx002.098

3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial

Autor: Volker, Gross, Ivan, Bunganic, Elena A, Belousova, Tatyana L, Mikhailova, Limas, Kupcinskas, Gediminas, Kiudelis, Zsolt, Tulassay, Libor, Gabalec, Andrey E, Dorofeyev, Jelena, Derova, Karin, Dilger, Roland, Greinwald, Ralph, Mueller, S V, Gridnieva

Publikováno v: Journal of Crohn'scolitis. 5(2)

Background and aims Budesonide may be an effective therapy for mild-to-moderately active ulcerative colitis (UC). This study aimed to demonstrate non-inferiority for oral 9mg budesonide once daily (OD) versus 3g mesalazine granules OD. Methods This w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc9237f9d130fe1539caad7423e37cc6
https://pubmed.ncbi.nlm.nih.gov/21453882